Genprex Dirección

Dirección controles de criterios 2/4

El CEO de Genprex's es John Varner , nombrado en Aug 2012, tiene una permanencia de 11.67 años. compensación anual total es $2.53M, compuesta por 22% salario y 78% primas, incluidas acciones y opciones de la empresa. posee directamente un 1% de las acciones de la empresa, por valor de €38.11K. La antigüedad media del equipo directivo y de la junta directiva es de 3.1 años y 4.1 años, respectivamente.

Información clave

John Varner

Chief Executive Officer (CEO)

US$2.5m

Compensación total

Porcentaje del salario del CEO	22.0%
Permanencia del CEO	11.7yrs
Participación del CEO	1.0%
Permanencia media de la dirección	3.1yrs
Promedio de permanencia en la Junta Directiva	4.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de John Varner en comparación con los beneficios de Genprex?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$31m
Sep 30 2023	n/a	n/a	-US$31m
Jun 30 2023	n/a	n/a	-US$30m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$3m	US$557k	-US$24m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$21m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$2m	US$480k	-US$21m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$18m
Mar 31 2021	n/a	n/a	-US$19m
Dec 31 2020	US$2m	US$488k	-US$18m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$659k	US$400k	-US$11m
Sep 30 2019	n/a	n/a	-US$12m
Jun 30 2019	n/a	n/a	-US$11m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$1m	US$338k	-US$12m
Sep 30 2018	n/a	n/a	-US$10m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$3m
Dec 31 2017	US$334k	US$300k	-US$3m

Compensación vs. Mercado: La compensación total de John($USD2.53M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD404.18K).

Compensación vs. Ingresos: La compensación de John ha aumentado mientras la empresa no es rentable.

CEO

John Varner (66 yo)

11.7yrs

Permanencia

US$2,532,399

Compensación

Mr. John Rodney Varner is a co-founder of Genprex, Inc. He has been the Chief Executive Officer and Chairman of Genprex, Inc. since August 2012 and has been its President since August 10, 2020. He served a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
John Varner	Co-Founder	11.7yrs	US$2.53m	1.0% $ 38.1k
Ryan Confer	Chief Financial Officer	7.6yrs	US$1.14m	0.35% $ 13.4k
David Schloss	Senior Vice President of Human Resources	2.3yrs	sin datos	sin datos
Thomas Gallagher	Senior Vice President of Intellectual Property & Licensing	3.6yrs	sin datos	sin datos
Mark Berger	Chief Medical Officer	2.6yrs	sin datos	0.25% $ 9.6k
Suzanne Thornton-Jones	Senior Vice President of Regulatory Affairs & Quality	less than a year	sin datos	sin datos
Jack Roth	Chairman of Scientific & Medical Advisory Board	no data	sin datos	sin datos

3.1yrs

Permanencia media

66yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2DE0 se considera experimentado (3.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
John Varner	Co-Founder	11.7yrs	US$2.53m	1.0% $ 38.1k
Jack Roth	Chairman of Scientific & Medical Advisory Board	no data	sin datos	sin datos
Brent Longnecker	Independent Director	4.1yrs	US$150.00k	0.046% $ 1.7k
James E. Rothman	Strategic Advisor to the Board of Directors	11.8yrs	sin datos	sin datos
Pasi Antero Janne	Member of Scientific & Medical Advisory Board	no data	sin datos	sin datos
George Peoples	Member of Clinical Advisory Board	3.2yrs	sin datos	sin datos
Shu Kam Mok	Member of Scientific & Medical Advisory Board	no data	sin datos	sin datos
George Simon	Member of Scientific & Medical Advisory Board	no data	sin datos	sin datos
William Wilson	Independent Director	4.1yrs	US$140.00k	0% $ 0
Jose Antonio Toscano	Independent Director	4.1yrs	US$150.00k	0% $ 0
George Gittes	Member of Scientific Advisory Board	3.4yrs	sin datos	sin datos
Michael Morse	Member of Clinical Advisory Board	3.2yrs	sin datos	sin datos

4.1yrs

Permanencia media

66.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 2DE0 se considera experimentada (4.1 años de antigüedad promedio).

Genprex Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

High number of new directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc. has completed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

New major risk - Market cap size

No longer forecast to breakeven

Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics

Genprex Receives Non-Compliance Notice From Nasdaq

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

Genprex, Inc. announced delayed 10-Q filing

Genprex, Inc. Receives Fast Track Designation from the FDA for Its Small Cell Lung Cancer Drug Candidate

Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers

Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cancer

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Genprex, Inc. Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy in Non-Small Cell Lung Cancer

Genprex, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

High number of new directors

High number of new and inexperienced directors

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

High number of new and inexperienced directors

High number of new and inexperienced directors

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

High number of new and inexperienced directors

Genprex, Inc. Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancercer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Announces Positive Preclinical Data for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System for Delivery of FAS DNA Plasmid to Treat Metastatic Colorectal Cancer

Genprex, Inc. to Accelerate Opening of Acclaim-1 Clinical Trial Sites

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc.(NasdaqCM:GNPX) dropped from Russell 3000E Index

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Forecast to breakeven in 2024

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. Announces Formation of Clinical Advisory Board

Genprex, Inc. Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer

Genprex, Inc Completes Manufacturing Technology Transfer for Novel Gene Therapy

Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. Appoints George K. Gittes to Its Scientific Advisory Board

Genprex, Inc. Promotes Eric Chapdelaine to Vice President of Manufacturing

Genprex, Inc. Names Thomas C. Gallagher, Esq. as Senior Vice President of Intellectual Property and Licensing

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad